MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
2.230
-0.030
-1.33%
Closed 16:00 07/19 EDT
OPEN
2.270
PREV CLOSE
2.260
HIGH
2.330
LOW
2.230
VOLUME
53.15K
TURNOVER
0
52 WEEK HIGH
5.24
52 WEEK LOW
1.040
MARKET CAP
45.92M
P/E (TTM)
-0.5965
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TARA last week (0708-0712)?
Weekly Report · 6d ago
Weekly Report: what happened at TARA last week (0701-0705)?
Weekly Report · 07/08 11:28
Weekly Report: what happened at TARA last week (0624-0628)?
Weekly Report · 07/01 11:28
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. Is a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases. Lisa Schlesinger will receive stock options to purchase 118,400 shares of common stock. The grant of inducement non-qualified stock options will be made in 2024.
Barchart · 06/24 16:06
Weekly Report: what happened at TARA last week (0617-0621)?
Weekly Report · 06/24 11:36
Weekly Report: what happened at TARA last week (0610-0614)?
Weekly Report · 06/17 11:27
Weekly Report: what happened at TARA last week (0603-0607)?
Weekly Report · 06/10 11:29
Weekly Report: what happened at TARA last week (0527-0531)?
Weekly Report · 06/03 11:32
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.